Generex Biotechnology Corporation
GNBT · OTC
7/31/2020 | 7/31/2019 | 7/31/2018 | 7/31/2017 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -57.1% | 782.2% | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 78.2% | 33.3% | 100% | – |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$21 | -$0 | -$0 |
| % Margin | -673.5% | -339,990.4% | -354.9% | – |
| Other Income/Exp. Net | -$0 | $19 | $0 | -$0 |
| Pre-Tax Income | -$0 | -$0 | $0 | -$0 |
| Tax Expense | -$0 | $0 | $0 | -$0 |
| Net Income | -$0 | -$0 | $0 | -$0 |
| % Margin | -1,252.7% | -150.6% | 5,166.6% | – |
| EPS | -0.46 | -0.14 | 0.67 | -2.41 |
| % Growth | -228.6% | -120.9% | 127.8% | – |
| EPS Diluted | -0.46 | -0.14 | 14.02 | -2.41 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$21 | $0 | -$0 |
| % Margin | -981.2% | -339,654.2% | 5,252.9% | – |